期刊
IMMUNOTHERAPY
卷 12, 期 6, 页码 395-406出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2019-0134
关键词
alpha-galactosylceramide; CNS; immunotherapy; lymphoma; NKT
类别
资金
- Cure Kids, New Zealand [CHRF 9499]
- Cancer Society of New Zealand Wellington Division
- Ministry of Business Innovation and Employment [RTV1603]
- Genesis Oncology Trust [GOT-1240-PGS, GOT-1548-RPG]
- Health Research Council of New Zealand [HRC 14/500]
- Thompson Family Foundation
- Genesis Oncology Trust
Aim: The efficacy of anti-lymphoma vaccines that exploit the cellular adjuvant properties of activated natural killer T (NKT) cells were examined in mouse models of CNS lymphoma. Materials & methods: Vaccines were prepared by either loading the NKT cell agonist, alpha-galactosylceramide onto irradiated and heatshocked B- and T-lymphoma cells, or chemically conjugating alpha-galactosylceramide to MHC-binding peptides from a lymphoma-associated antigen. Vaccine efficacy was analyzed in mice bearing intracranial tumors. Results: Both forms of vaccine proved to be effective in preventing lymphoma engraftment through activity of T cells that accessed the CNS. Established lymphoma was harder to treat with responses constrained by Tregs, but this could be overcome by depleting Tregs prior to vaccination. Conclusion: Simply designed NKT cell-activating vaccines enhance T-cell responses and have the potential to protect against CNS lymphoma development or prevent CNS relapse. To be effective against established CNS lymphoma, vaccines need to be combined with Treg suppression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据